Advertisement

FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

      Abstract

      Background

      A novel formulation of bosentan was evaluated in children with pulmonary arterial hypertension (PAH) in FUTURE-1, which characterized its pharmacokinetic and clinical profile. The subsequent phase III, open-label, long-term extension study, FUTURE-2, aimed to provide long-term tolerability, safety and exploratory efficacy data.

      Methods

      Children (≥2 and <12 years) with idiopathic or heritable PAH, who completed 12-week treatment in FUTURE-1 and for whom bosentan was considered beneficial were enrolled, and continued to receive bosentan 4 mg/kg twice-daily, which could be down-titrated to 2 mg/kg if not tolerated. Safety and tolerability were evaluated via treatment-emergent adverse events (AEs), serious AEs, growth, and laboratory measurements. Exploratory efficacy endpoints included time to PAH worsening and long-term survival. All analyses were conducted on pooled data of both studies.

      Results

      36 patients were enrolled in FUTURE-1 and 33 continued in FUTURE-2. The overall median duration of exposure to bosentan was 27.7 (range 1.9–59.6) months. Treatment-emergent AEs occurred in 32 (88.9%) patients; AEs considered treatment-related in 15 (41.7%) patients. Of 51 serious AEs, three were considered treatment-related: two incidences of reported PAH worsening and one of autoimmune hepatitis. Six deaths occurred; none were considered treatment-related. Kaplan–Meier event-free estimates of PAH worsening were 78.9% and 73.6% at 2 and 4 years, respectively.

      Conclusions

      The pediatric bosentan formulation was generally well tolerated, its safety profile comparable to that of the adult formulation when used in children. The results are in line with the efficacy profile of bosentan in previous pediatric and adult PAH studies of shorter duration.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoeper M.M.
        • Bogaard H.J.
        • Condliffe R.
        • et al.
        Definitions and diagnosis of pulmonary hypertension.
        J. Am. Coll. Cardiol. 2013; 62: D42-D50
        • Barst R.J.
        • Ertel S.I.
        • Beghetti M.
        • Ivy D.D.
        Pulmonary arterial hypertension: a comparison between children and adults.
        Eur. Respir. J. 2011; 37: 665-677
        • Badesch D.B.
        • Champion H.C.
        • Sanchez M.A.
        • et al.
        Diagnosis and assessment of pulmonary arterial hypertension.
        J. Am. Coll. Cardiol. 2009; 54: S55-S66
        • Ivy D.D.
        • Abman S.H.
        • Barst R.J.
        • et al.
        Pediatric pulmonary hypertension.
        J. Am. Coll. Cardiol. 2013; 62: D117-D126
        • Berger R.M.F.
        • Beghetti M.
        • Humpl T.
        • et al.
        Clinical features of paediatric pulmonary hypertension: a registry study.
        Lancet. 2012; 379: 537-546
        • McGoon M.D.
        • Miller D.P.
        REVEAL: a contemporary US pulmonary arterial hypertension registry.
        Eur. Respir. Rev. 2012; 21: 8-18
        • Barst R.J.
        • McGoon M.D.
        • Elliott C.G.
        • Foreman A.J.
        • Miller D.P.
        • Ivy D.D.
        Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
        Circulation. 2012; 125: 113-122
        • Zijlstra W.M.H.
        • Douwes J.M.
        • Rosenzweig E.B.
        • et al.
        Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies.
        J. Am. Coll. Cardiol. 2014; 63: 2159-2169
        • van Loon R.L.
        • Roofthooft M.T.R.
        • Hillege H.L.
        • et al.
        Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.
        Circulation. 2011; 124: 1755-1764
        • Haworth S.G.
        • Hislop A.A.
        Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006.
        Heart. 2009; 95: 312-317
        • Manes A.
        • Palazzini M.
        • Leci E.
        • Bacchi Reggiani M.L.
        • Branzi A.
        • Galiè N.
        Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.
        Eur. Heart J. 2014; 35: 716-724
        • Adatia I.
        • Haworth S.G.
        • Wegner M.
        • et al.
        Clinical trials in neonates and children: report of the pulmonary hypertension academic research consortium pediatric advisory committee.
        Pulm. Circ. 2013; 3: 252-266
        • Rosenzweig E.B.
        • Ivy D.D.
        • Widlitz A.
        • et al.
        Effects of long-term bosentan in children with pulmonary arterial hypertension.
        J. Am. Coll. Cardiol. 2005; 46: 697-704
        • Maiya S.
        • Hislop A.A.
        • Flynn Y.
        • Haworth S.G.
        Response to bosentan in children with pulmonary hypertension.
        Heart. 2006; 92: 664-670
        • Hislop A.A.
        • Moledina S.
        • Foster H.
        • Schulze-Neick I.
        • Haworth S.G.
        Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
        Eur. Respir. J. 2011; 38: 70-77
        • van Loon R.L.
        • Hoendermis E.S.
        • Duffels M.G.J.
        • Vonk-Noordegraaf A.
        • Mulder B.J.M.
        • Hillege H.L.
        • Berger R.M.F.
        Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?.
        Am. Heart J. 2007; 154: 776-782
        • Barst R.J.
        • Ivy D.
        • Dingemanse J.
        • et al.
        Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
        Clin. Pharmacol. Ther. 2003; 73: 372-382
        • Beghetti M.
        • Haworth S.G.
        • Bonnet D.
        • et al.
        Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.
        Br. J. Clin. Pharmacol. 2009; 68: 948-955
        • ICH Harmonised Tripartite Guideline
        Clinical safety data management: definitions and standards for expedited reporting E2A.
        (Version 27 October 1994. Available at:) (Accessed 26 May 2015)
        • Berger R.M.F.
        Pulmonary hypertension: smaller kids, smaller steps.
        Lancet Respir. Med. 2014; 2: 348-350
        • Channick R.N.
        • Simonneau G.
        • Sitbon O.
        • et al.
        Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
        Lancet. 2001; 358: 1119-1123
        • Rubin L.J.
        • Badesch D.B.
        • Barst R.J.
        • et al.
        Bosentan therapy for pulmonary arterial hypertension.
        N. Engl. J. Med. 2002; 346: 896-903
        • Galiè N.
        • Rubin L.
        • Hoeper M.
        • et al.
        Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
        Lancet. 2008; 371: 2093-2100
        • Ivy D.D.
        • Rosenzweig E.B.
        • Lemarié J.C.
        • Brand M.
        • Rosenberg D.
        • Barst R.J.
        Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
        Am. J. Cardiol. 2010; 106: 1332-1338
        • Beghetti M.
        • Hoeper M.M.
        • Kiely D.G.
        • Carlsen J.
        • Schwierin B.
        • Segal E.S.
        • Humbert M.
        Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.
        Pediatr. Res. 2008; 64: 200-204
        • van Loon R.L.
        • Roofthooft M.T.R.
        • Delhaas T.
        • et al.
        Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies.
        Am. J. Cardiol. 2010; 106: 117-124
        • D'Alonzo G.E.
        • Barst R.J.
        • Ayres S.M.
        • et al.
        Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.
        Ann. Intern. Med. 1991; 115: 343-349
        • Barst R.J.
        • Maislin G.
        • Fishman A.P.
        Vasodilator therapy for primary pulmonary hypertension in children.
        Circulation. 1999; 99: 1197-1208
        • Sandoval J.
        • Bauerle O.
        • Gomez A.
        • Palomar A.
        • Martínez Guerra M.L.
        • Furuya M.E.
        Primary pulmonary hypertension in children: clinical characterization and survival.
        J. Am. Coll. Cardiol. 1995; 25: 466-474
        • Beghetti M.
        Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs.
        Eur. Respir. Rev. 2009; 18: 18-23

      Linked Article